Biohaven (BHVN) is positioned as a potential high-growth biotech play similar to Moderna's trajectory, with pipeline candidates and development potential. Key risks include clinical trial failures, regulatory setbacks, competitive pressure from larger pharma, and typical biotech execution risk.